Harrow Stock Gains 12% on FDA Approval for Eye Drug
2h ago|3 min readQuick Read
Fazen Markets Editorial Desk
Collective editorial team · methodology
harrow-inchrow-stock
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Harrow, Inc. shares advanced 12.4% to close at $15.80 on June 13, 2026, following the company's announcement that the U.S. Food and Drug Administration granted approval for IOPIDINE (apraclonidine ophthalmic solution) 0.5%. The regulatory milestone marks a significant shift for the specialty pharmaceutical company, which has historically derived the majority of its revenue from compounded formulations. The approval expands Harrow's commercial portfolio with its first owned proprietary product.
The FDA's approval arrives as the agency faces scrutiny over its handling of compounded drug regulations. A 2025 policy shift increased oversight on compounding pharmacies, creating a more challenging operating environment for companies reliant on that business model. This regulatory pressure incentivized Harrow to accelerate its pipeline of proprietary products to diversify its revenue streams.
The current macro backdrop for small-cap biopharma remains favorable for companies achieving de-risking events. The Russell 2000 Biotechnology Index has gained 15% year-to-date, outperforming the broader S&P 500's 8% return. This outperformance reflects investor appetite for clinical and regulatory catalysts that demonstrate clear paths to commercialization.
Harrow's transition mirrors a strategy employed by other specialty pharma companies facing regulatory headwinds. In 2023, Akorn Pharmaceuticals pivoted toward proprietary development after compounding revenue declined 22% following increased FDA enforcement. The successful execution of such pivots often requires significant capital investment and timely regulatory approvals.
Harrow's market capitalization increased by approximately $48 million following the approval news, reaching $432 million. Trading volume surged to 1.8 million shares, nearly five times its 30-day average volume of 380,000 shares. The stock's move outperformed the iShares Biotechnology ETF (IBB), which was flat on the session.
Before the announcement, Harrow stock had declined 18% year-to-date, underperforming the broader healthcare sector. Short interest stood at 12% of float, indicating significant skepticism toward the company's ability to successfully transition to proprietary products. The approval potentially creates a short squeeze scenario if bullish momentum continues.
Financial metrics show the importance of this diversification. Compounded products represented 84% of Harrow's 2025 revenue of $148 million. IOPIDINE targets a glaucoma market estimated at $800 million annually in the United States. The company has not provided specific revenue guidance for the newly approved product.
The approval creates positive sentiment for other ophthalmology-focused companies with late-stage pipelines. Tickers such as Aerie Pharmaceuticals (AERI) and Ocular Therapeutix (OCUL) saw modest gains of 2-3% in sympathy trading. Equipment suppliers like Bausch + Lomb (BLCO) could see increased demand if IOPIDINE adoption drives more office-based procedures.
A key risk involves commercial execution. Harrow must now build a dedicated sales force and marketing apparatus for a proprietary product, a capability it hasn't previously demonstrated at scale. The company's operating expenses may increase significantly before revenue from IOPIDINE materially contributes to profitability.
Institutional flow data indicates mixed positioning. Several healthcare-focused hedge funds established small long positions in Harrow throughout 2026, while some generalist funds remained underweight or short. The approval may force covering among bearish investors who doubted Harrow's regulatory strategy.
Investors should monitor Harrow's second quarter 2026 earnings call, typically held in early August. Management will likely provide initial prescription data and early commercialization metrics for IOPIDINE. Any guidance on pricing, insurance reimbursement, or initial sales force productivity will be critical for assessing the product's potential.
Key technical levels include resistance at $17.50, which represents the stock's 52-week high from November 2025. Support now establishes at $14.20, the pre-announcement closing price. A break above $17.50 on sustained volume could indicate continued momentum.
The company faces a catalyst in Q4 2026 with potential FDA decision on another pipeline product, HEALON (hyaluronic acid). Positive regulatory action on multiple products could validate Harrow's broader R&D strategy and improve investor confidence in its transition away from compounding dependence.
The FDA approval reduces reliance on the compounding business, which faces regulatory uncertainty. A successful proprietary product launch could significantly improve profit margins and provide more predictable revenue streams. Long-term investors should watch prescription growth rates and market share gains against established competitors in the glaucoma space.
Harrow's entire 2025 revenue was $148 million. The U.S. glaucoma market is estimated at $800 million annually, though IOPIDINE will compete against multiple established brands. Capturing even 5% market share would represent approximately $40 million in annual revenue, which would materially diversify the company's revenue composition.
Commercial execution risk is the primary concern. The company must effectively launch and market IOPIDINE against entrenched competitors with larger sales forces. the compounding business may continue to face regulatory pressure, potentially offsetting gains from the new product if the transition occurs too slowly.
Harrow's FDA approval marks a critical inflection point toward becoming a diversified pharmaceutical company.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.